We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ASI to Manufacture Amotosalen Active Pharmaceutical Ingredient
News

ASI to Manufacture Amotosalen Active Pharmaceutical Ingredient

ASI to Manufacture Amotosalen Active Pharmaceutical Ingredient
News

ASI to Manufacture Amotosalen Active Pharmaceutical Ingredient

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ASI to Manufacture Amotosalen Active Pharmaceutical Ingredient"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ash Stevens, Inc. (ASI) has announced the U.S Food and Drug Administration (FDA) has approved ASI's manufacturing facility in Riverview, Michigan for the manufacture of Amotosalen, the API in Cerus Corporation's INTERCEPT Blood System.

The INTERCEPT Blood System recently received FDA approval for ex vivo preparation of pathogen reduced plasma and platelet components in order to reduce the risk of transfusion-transmitted infection (TTI).

“We are proud to be Cerus Corporation’s outsourcing partner for the development and manufacture of this important API. We have had a collaborative and highly productive relationship with Cerus for many years and we are excited to help provide this innovative product to patients. This is a particularly heartwarming approval for me as I witnessed the fundamental research which led to this important product during my time as a graduate student in Professor Henry Rapoport’s lab at The University of California, Berkeley.” Says Dr. Stephen Munk President and CEO of Ash Stevens Inc. This represents ASI’s twelfth manufacturing approval for an innovator or NCE (New Chemical Entity) drug.

Advertisement